Related Experiment Video
Updated: May 16, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Neonatal abstinence syndrome: therapeutic interventions
1University Hospital, Neonatal Intensive Care Unit, Cincinnati, OH, USA. juliannsublett@gmail.com
Insights
Neonatal Abstinence Syndrome (NAS) is a severe condition in infants exposed to drugs during pregnancy. This review examines the safety and efficacy of pharmacologic and nonpharmacologic treatments for NAS, highlighting knowledge gaps.
Area of Science:
- Neonatal Abstinence Syndrome (NAS)
- Pediatric Pharmacology
- Neonatal Care
Background:
- NAS affects infants exposed to opiates/illicit drugs in utero, causing severe symptoms and prolonged hospitalizations.
- Pharmacologic treatments like methadone, buprenorphine, morphine, and phenobarbital are common but lack fully recognized safety/efficacy data.
- Nonpharmacologic and complementary therapies are documented but under-researched for neonatal withdrawal.
Purpose of the Study:
- To provide an overview of pharmacologic and complementary therapies for NAS.
- To assess the potential risks, benefits, and outcomes of these treatments in neonates.
- To identify and illustrate gaps in the current literature regarding NAS therapies.
Main Methods:
- Literature review of pharmacologic interventions for NAS.
- Review of nonpharmacologic and complementary therapies for neonatal withdrawal.
- Analysis of existing data on safety, efficacy, and outcomes.
Main Results:
- Pharmacologic treatments are widely used but their safety and efficacy require further investigation.
- Nonpharmacologic and complementary therapies show promise but lack comprehensive research.
- Significant gaps exist in understanding the full spectrum of treatment options and their impact.
Conclusions:
- Further research is crucial to establish evidence-based guidelines for NAS treatment.
- A comprehensive understanding of both pharmacologic and nonpharmacologic approaches is needed.
- Addressing knowledge gaps will improve care and outcomes for infants with NAS.
Abstract:
Neonatal Abstinence Syndrome (NAS) occurs in infants exposed to opiates or illicit drugs during pregnancy. It can be severe and cause long hospital stays after birth and with symptoms up to 6 months after birth. Pharmacologic interventions are commonly used as treatment for NAS; however, their safety and efficacy are not fully recognized. Pharmacologic treatments for NAS include medications such as methadone, buprenorphine, morphine, and phenobarbital. Nonpharmacologic interventions and complementary therapies have been documented in neonates. However, there are gaps in the literature regarding use of these therapies for neonatal withdrawal. This article provides an overview of the possible risks, benefits, and outcomes of pharmacologic and complementary therapies in the neonatal population, and illustrates the gaps in knowledge related to their use for neonatal withdrawal.
More Related Videos
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Related Concept Videos
CNS Depressants: Alcohol and Nicotine
Drug Dependence
Drug Abuse and Addiction: Pharmacological Phenomena
CNS Depressants: Barbiturates and Benzodiazepines
Pharmaceutical Poisoning: Treatment Strategies
Operant Conditioning Intervention
In operant conditioning, behaviors that are...